TY - JOUR
T1 - Hypotic medication use among inpatients with schizophrenia and major depressive disorder
T2 - results of a nationwide study
AU - Furihata, Ryuji
AU - Otsuki, Rei
AU - Hasegawa, Naomi
AU - Tsuboi, Takashi
AU - Numata, Shusuke
AU - Yasui-Furukori, Norio
AU - Kashiwagi, Hiroko
AU - Hori, Hikaru
AU - Ochi, Shinichiro
AU - Muraoka, Hiroyuki
AU - Onitsuka, Toshiaki
AU - Komatsu, Hiroshi
AU - Takeshima, Masahiro
AU - Hishimoto, Akitoyo
AU - Nagasawa, Tatsuya
AU - Takaesu, Yoshikazu
AU - Nakamura, Toshinori
AU - Asami, Takeshi
AU - Miura, Kenichiro
AU - Matsumoto, Junya
AU - Ohi, Kazutaka
AU - Yasuda, Yuka
AU - Iida, Hitoshi
AU - Ogasawara, Kazuyoshi
AU - Hashimoto, Naoki
AU - Ichihashi, Kayo
AU - Yamada, Hisashi
AU - Watanabe, Koichiro
AU - Inada, Ken
AU - Hashimoto, Ryota
N1 - Funding Information:
This study was supported by the Japan Agency for Medical Research and Development (AMED) under Grant Number JP16dk0307060 , and AMED under Grant Number JP19dk0307083 , the Health and Labor Sciences Research Grants (H29-Seishin-Ippan-001, 19GC1201 ), the Japanese Society of Neuropsychopharmacology , the Japanese Society of Mood Disorders and the Japanese Society of Clinical Neuropsychopharmacology . Ryuji Furihata is supported by a Research Grant from the Japan Society for Promoting Science and Technology Agency ( 20K07967 , 2020–2022).
Publisher Copyright:
© 2021 Elsevier B.V.
PY - 2022/1
Y1 - 2022/1
N2 - Study objectives: To investigate the proportion of inpatients with schizophrenia and major depressive disorder prescribed hypnotic medication, and the association between such medication and the use of other antipsychotic agents. Methods: This was a nationwide cross-sectional study performed as part of the ‘Effectiveness of Guidelines for Dissemination and Education in Psychiatric Treatment’ (EGUIDE) project. Data from 2146 inpatients with schizophrenia and 1031 inpatients with major depressive disorder were analyzed. All types and dosages of psychotropic drugs were recorded and the data at the time of discharge were analyzed. Associations between the use of hypnotic medication and other antipsychotic agents were evaluated using multivariate logistic regression analyses. Results: The proportions of schizophrenia patients who were prescribed any and two or more hypnotic agents were 55.7% and 17.6%, respectively, and the corresponding proportions for patients with major depressive disorder were 63.6% and 22.6%, respectively. In schizophrenia patients, multivariate logistic regression analyses showed that two or more antipsychotics, anticholinergic drugs, anxiolytics, and mood stabilizers/antiepileptic drugs were positively associated with the use of any hypnotic agent. In patients with major depressive disorder, multivariate logistic regression analyses revealed that two or more antidepressants, two or more antipsychotics, anxiolytics, and mood stabilizers/antiepileptic drugs were positively associated with the use of any hypnotic agent. Conclusions: Prescription of hypnotic agents was found to be highly frequent among inpatients with psychiatric disorders. Prescription of two or more main antipsychotic agents was commonly associated with the use of hypnotic medication for both schizophrenia and major depressive disorder.
AB - Study objectives: To investigate the proportion of inpatients with schizophrenia and major depressive disorder prescribed hypnotic medication, and the association between such medication and the use of other antipsychotic agents. Methods: This was a nationwide cross-sectional study performed as part of the ‘Effectiveness of Guidelines for Dissemination and Education in Psychiatric Treatment’ (EGUIDE) project. Data from 2146 inpatients with schizophrenia and 1031 inpatients with major depressive disorder were analyzed. All types and dosages of psychotropic drugs were recorded and the data at the time of discharge were analyzed. Associations between the use of hypnotic medication and other antipsychotic agents were evaluated using multivariate logistic regression analyses. Results: The proportions of schizophrenia patients who were prescribed any and two or more hypnotic agents were 55.7% and 17.6%, respectively, and the corresponding proportions for patients with major depressive disorder were 63.6% and 22.6%, respectively. In schizophrenia patients, multivariate logistic regression analyses showed that two or more antipsychotics, anticholinergic drugs, anxiolytics, and mood stabilizers/antiepileptic drugs were positively associated with the use of any hypnotic agent. In patients with major depressive disorder, multivariate logistic regression analyses revealed that two or more antidepressants, two or more antipsychotics, anxiolytics, and mood stabilizers/antiepileptic drugs were positively associated with the use of any hypnotic agent. Conclusions: Prescription of hypnotic agents was found to be highly frequent among inpatients with psychiatric disorders. Prescription of two or more main antipsychotic agents was commonly associated with the use of hypnotic medication for both schizophrenia and major depressive disorder.
UR - http://www.scopus.com/inward/record.url?scp=85120449028&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85120449028&partnerID=8YFLogxK
U2 - 10.1016/j.sleep.2021.11.005
DO - 10.1016/j.sleep.2021.11.005
M3 - Article
C2 - 34875519
AN - SCOPUS:85120449028
SN - 1389-9457
VL - 89
SP - 23
EP - 30
JO - Sleep Medicine
JF - Sleep Medicine
ER -